In this Healio Video Perspective from the ASRS meeting, Arshad M. Khanani, MD, MA, FASRS, discusses the just-released 4-year efficacy and safety outcomes of faricimab in diabetic macular edema.
Khanani said the RHONE-X extension study found that patients maintained the vision and central subfield thickness improvements seen in the YOSEMITE and RHINE trials, and absence of DME was achieved in more than 90% of patients by the end of the study. In addition, faricimab was well tolerated through years 3 and 4 of RHONE-X.
“I think this dataset is very relevant for clinicians,” he said. “Where